Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 14/20 | 0.63 |
| ▸ | F2 | P00734 | 13/20 | 0.63 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | F7 | P08709 | 8/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 7/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 7/20 | 0.47 |
| ▸ | F12 | P00748 | 3/20 | 0.45 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437118 | 1.00 | F11 (0.63) | F11F2F10F7PRSS1 | |
| SCHEMBL6439143 | 0.95 | F11 (0.57) | F11F2F10F7PRSS1 | |
| SCHEMBL6439146 | 0.95 | F11 (0.57) | F11F2F10F7PRSS1 | |
| SCHEMBL6438717 | 0.94 | F2 (0.55) | F11F2F10F7PRSS1 | |
| SCHEMBL6438710 | 0.94 | F2 (0.55) | F11F2F10F7PRSS1 | |
| SCHEMBL3767038 | 0.94 | F11 (0.65) | F11F2F10F7PRSS1 | |
| SCHEMBL6438340 | 0.94 | F11 (0.65) | F11F2F10F7PRSS1 | |
| SCHEMBL6440344 | 0.93 | F11 (0.65) | F11F2F10F7PRSS1 | |
| SCHEMBL6440348 | 0.93 | F11 (0.65) | F11F2F10F7PRSS1 | |
| SCHEMBL6436848 | 0.91 | F11 (0.63) | F11F2F10F7PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |